August 22, 2023 Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization
April 17, 2023 Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions
August 25, 2022 Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy
June 28, 2020 Asieris Announced the Completion of Series C+ Round Financing – to Accelerate the Commercialization
March 24, 2020 Asieris Announced the Completion of Series C Round Financing- to Accelerate the Global Development of Its Innovative Drugs
